AIM Rule 26

The information below is supplied for the purposes of complying with AIM Rule 26 and was last updated on 19 April 2016.

Company Amryt Pharma’s strategy is to build a specialty pharmaceutical company focused on the development and commercialisation of drugs to treat rare and orphan diseases.
Directors Harry Stratford (Non-Executive Chairman)
Joe Wiley (CEO)
Rory Nealon (CFO/COO)
James Culverwell (Non-Executive Director)
Ray Stafford (Non-Executive Director)
Cathal Friel (Non-Executive Director)
Markus Ziener (Non-Executive Director)

View management team biographies

Corporate Governance A description of the responsibilities of the members
Country of Incorporation Amryt Pharma is a UK incorporated company
Articles of Association Articles of Association - amended 18 April 2016
Other exchanges Amryt Pharma is listed on the AIM market of the London Stock Exchange (Ticker: AMYT) and the Enterprise Securities Market (ESM) of the Irish Stock Exchange (Ticker: AYP).
Number of securities in issue, shares not in public hands and significant shareholders Total number of shares issued: 208,339,631
Number of shares (if any) held in treasury: Nil

Shareholders with >3% of total issued:

Name Number of shares Percentage of issued share capital
Software AG-Stiftung 43,545,567 20.90%
Cathal Friel 33,077,347 15.88%
Joseph Wiley 20,772,895 9.97%
Axa Framlington 20,625,000 9.90%
Rory Nealon 9,443,031 4.53%
Alan Harris 8,869,090 4.26%

Pursuant to the AIM Rules, and insofar as the Company is aware, as at 19/04/16, 62.6% of the Company’s AIM securities were not in public hands

Restrictions there are no restrictions on the transfer of Ordinary Shares;
Financial Information Click to view the latest Annual Report and Interim Results of the company
Notifications Click to view Amryt’s latest regulatory news
Admission Document & Circulars Click to view the Company Admission document and Shareholder Circulars
Advisers Click to view the Company’s list of advisers
Takeover Code The Company is subject to the City Code on Takeovers and Mergers.

Email Alerts

Subscribe to Our Newsletter:

Delivered by Investis – link to website (opens in a new window)